Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Phase 3 REMARC Trial Data with REVLIMID in DLBCL Maintenance Due Q4 2016

Source Link:: http://ir.celgene.com/releasedetail.cfm?ReleaseID=952157

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

CELG

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details Data from the Phase 3 Remarc Trial of Revlimid (lenalidomide) on patients with diffuse large b-cell lymphoma is expected in 2016. The study primary completion date is projected in September.

http://ir.celgene.co...

Clinical Data Update on July 25 2016: REMARC achieved the primary endpoint of a statistically significant improvement in progression-free survival for patients receiving REVLIMID®. The interim analysis of overall survival, a key secondary endpoint, showed no benefit in the REVLIMID® arm. Based upon these interim results, Celgene does not currently plan to seek approval for this indication.

http://ir.celgene.co...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Jul 25, 2016

Occurred Source:

http://ir.celgene.com/releasedetail.cfm?releaseid=981035

Related Projects

What Can We Expect from Celgene's Phase 3 REMARC Trial Data for Non-Hodgkin Lymphoma? CELG Execute By: Aug 31, 2016

Related Keywords Phase 3 Data, Remarc Trial, Revlimid, Lenalidomide, Diffuse Large B-cell Lymphoma